Medline (NASDAQ:MDLN) Given Consensus Rating of “Moderate Buy” by Analysts

Medline (NASDAQ:MDLN) has been assigned a consensus rating of “Moderate Buy” from the twenty-nine analysts that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have issued a hold recommendation, twenty-two have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $50.5385.

Several analysts have recently commented on the company. Deutsche Bank Aktiengesellschaft set a $42.00 price objective on Medline in a report on Thursday, May 7th. JPMorgan Chase & Co. increased their price target on Medline from $50.00 to $53.00 and gave the company an “overweight” rating in a research note on Tuesday, March 10th. Robert W. Baird lowered their price target on Medline from $57.00 to $45.00 and set an “outperform” rating for the company in a report on Wednesday, June 3rd. Sanford C. Bernstein dropped their price target on Medline from $56.00 to $54.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Finally, BTIG Research restated a “buy” rating and set a $55.00 price objective on shares of Medline in a report on Thursday, May 7th.

Insider Activity at Medline

In other Medline news, insider Douglas P. Golwas sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $36.77, for a total transaction of $3,677,000.00. Following the sale, the insider owned 23,899 shares of the company’s stock, valued at approximately $878,766.23. The trade was a 80.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jessi L. Corcoran purchased 5,000 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was bought at an average cost of $34.15 per share, with a total value of $170,750.00. Following the acquisition, the insider owned 5,000 shares of the company’s stock, valued at approximately $170,750. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. 0.81% of the stock is currently owned by insiders.

Institutional Trading of Medline

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sound Income Strategies LLC purchased a new stake in Medline during the 4th quarter valued at about $25,000. Entrust Financial LLC purchased a new position in shares of Medline in the fourth quarter worth about $26,000. NBC Securities Inc. acquired a new stake in shares of Medline during the fourth quarter worth about $28,000. Whipplewood Advisors LLC acquired a new stake in shares of Medline during the first quarter worth about $30,000. Finally, Global Retirement Partners LLC purchased a new stake in Medline in the fourth quarter valued at approximately $31,000.

Medline Price Performance

NASDAQ MDLN opened at $43.19 on Monday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.51 and a current ratio of 4.41. The company has a market cap of $56.74 billion and a price-to-earnings ratio of 134.97. The stock’s 50 day moving average price is $38.38. Medline has a 52 week low of $32.81 and a 52 week high of $50.88.

Medline (NASDAQ:MDLN) last announced its earnings results on Wednesday, May 6th. The company reported $0.33 earnings per share for the quarter, beating the consensus estimate of $0.29 by $0.04. The firm had revenue of $7.35 billion during the quarter. Medline’s quarterly revenue was up 10.7% compared to the same quarter last year. On average, equities research analysts anticipate that Medline will post 1.49 earnings per share for the current fiscal year.

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.